NCT02917070 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortalit
Gumprecht J, Zychma MJ, Grzeszczak W, Zukowska-Szczechowska E; End-stage Renal Disease Study Group
Human SA gene Pst1 polymorphism and chronic renal failure: results of the family-based study. Nephrol Dial Transplant. 2001 Feb;16(2):387-90.
National Kidney Foundation
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.
O'Dea DF, Murphy SW, Hefferton D, Parfrey PS
Higher risk for renal failure in first-degree relatives of white patients with end-stage renal disease: a population-based study. Am J Kidney Dis. 1998 Nov;32(5):794-801.
Süleymanlar G, Utas C, Arinsoy T, Ates K, Altun B, Altiparmak MR, Ecder T, Yilmaz ME, Çamsari T, Basçi A, Odabas AR, Serdengeçti K
A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study. Nephrol Dial Transplant. 2011 Jun;26(6):186

The Importance of Parental Consanguinity and Family History of Kidney Disease in Turkish Adult Chronic Kidney Disease Population

Clinical trial NCT02917070 - References